Efficacy and safety of factor Xa inhibitors. Heterogeneity overall I² = 0%, P = .43; major bleeding I² = 69%, P = .02; intracranial bleeding I² = 0%, P = .60; major gastrointestinal bleeding I² = 62%, P = .05; fatal bleeding I² = 0%, P = .72; CRNM bleeding I² = 89%, P = .13; net clinical benefit I² = 11%, P = .34; all-cause mortality I² = 10%, P = .34. Xa-inhibitor, oral direct factor Xa inhibitor.